Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Floradapt
- Development stage
- Unknown
- Lead developer
- Kaneka
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Floradapt is a line of clinical-strain probiotic supplements developed and marketed by Kaneka Probiotics, a division of Kaneka Corporation. The product line is formulated with specific, clinically documented bacterial strains, primarily from the *Lactobacillus plantarum* and *Pediococcus acidilactici* species, to target distinct health areas such as digestive health, immune defense, cardiovascular health, and infant colic. The "Mature Immune Defense" formulation is specifically designed for the elderly population to enhance nutrient absorption and support the immune system by modulating markers like secretory immunoglobulin A (sIgA) and cortisol. These probiotics are selected for their ability to survive gastrointestinal transit and exert targeted physiological effects, positioning them as evidence-based nutraceuticals supported by clinical trial data.
- Brand names
- FloradaptFloradapt Mature Immune DefenseFloradapt CardioFloradapt Intensive GIFloradapt Baby ColicFloradapt Oral Health
- Other names
- Kaneka Floradapt
02
Targets
sIgA (Secretory immunoglobulin A)
Beyond the preview
Go deeper on Floradapt.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Floradapt.